Results 101 to 110 of about 126,260 (296)

A phenomap of TTR amyloidosis to aid diagnostic screening

ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos, Theodoros Tsampras, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos   +4 more
wiley   +1 more source

Persistent proteinuria is associated with the occurrence of cardiovascular disease: a nationwide population-based cohort study

Scientific Reports
Proteinuria is an important risk factor for cardiovascular disease (CVD) and acts as a surrogate marker of renal damage. This study aimed to determine the association between changes in proteinuria and the occurrence of CVD.
Ho Geol Woo, Moo-Seok Park, Tae-Jin Song
doaj   +1 more source

Proteinuria, Chronic Kidney Disease, and the Effect of an Angiotensin Receptor Blocker in Addition to an Angiotensin-Converting Enzyme Inhibitor in Patients With Moderate to Severe Heart Failure [PDF]

, 2009
Inder S. Anand, Kalkidan Bishu, Thomas S. Rector, Areef Ishani, Michael A. Kuskowski, Jay N. Cohn   +5 more
openalex   +1 more source

Proteinuria

BMJ, 2006
Haynes, J, Haynes, R
openaire   +4 more sources

A Delphi consensus project to capture experts' opinion on hyperkalaemia management across the cardiorenal spectrum

ESC Heart Failure, Volume 12, Issue 2, Page 1132-1140, April 2025.
Abstract The main purpose of this project was to capture experts' opinion on hyperkalaemia management and form best practice recommendations for cardiorenal patients in Greece. A steering committee of nephrologists and cardiologists developed 37 statements. An online questionnaire completed by 32 experts in cardiorenal management in Greece.
Christina Chrysohoou, Maria Marketou, Maria Aktsiali, Ioannis Griveas   +3 more
wiley   +1 more source

Is loss of podocyte foot processes necessary for the induction of proteinuria? [PDF]

, 2005
S. Ananth Karumanchi, Franklin H. Epstein, Isaac E. Stillman   +2 more
openalex   +1 more source

Lymphadenopathy and proteinuria [PDF]

Nephrology Dialysis Transplantation, 2004
Svetlana, Karie, Hassane, Izzedine, Hélène, Beaufils, Frederic, Charlotte, Vincent, Launay-Vacher, Gilbert, Deray   +5 more
openaire   +2 more sources

Mycophenolate mofetil and telmisartan for the treatment of proteinuria secondary to minimal change disease podocytopathy in a dog [PDF]

, 2022
Victoria Travail, Rachel E. Cianciolo, Kerry Peak, Andrea Di Bella   +3 more
openalex   +1 more source

Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT‐MI

ESC Heart Failure, EarlyView.
Impact of empagliflozin in patients with and without T2D or CKD in the EMPACT‐MI trial. Baseline characteristics, HF outcomes and subgroup analysis of efficacy endpoints are shown. # Hazard ratios estimated via Cox proportional hazard model (unless indicated otherwise). ^ Rate ratios via negative binomial regression.
Francesco Fioretti, Javed Butler, Jacob A. Udell, W. Schuyler Jones, Mark C. Petrie, Josephine Harrington, Michaela Mattheus, Johann Bauersachs, Antoni Bayes‐Genis, Shaun G. Goodman, Tomasz Gasior, James L. Januzzi, Renato D. Lopes, Piotr Ponikowski, Xavier Rossello, Morten Schou, Peter van der Meer, Dragos Vinereanu, Shelley Zieroth, Martina Brueckmann, Mikhail Sumin, Deepak L. Bhatt, Adrian F. Hernandez, Stefan D. Anker   +23 more
wiley   +1 more source

Evaluation of Renal Function in Obese Children and Adolescents Using Serum Cystatin C Levels, Estimated Glomerular Filtration Rate Formulae and Proteinuria: Which is most Useful?

, 2019
Dilşah Önerli Salman, Zeynep Şıklar, Nisa Eda Çullas İlarslan, Zeynep Birsin Özçakar, Pınar Kocaay, Merih Berberoğlu   +5 more
openalex   +1 more source